Overcoming Deadly Diseases
A new class of selective therapies demonstrating potential against gliomas, leukemia and other cancers
The first antiviral approved for the treatment of smallpox in all age groups
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties